© 2022 MJH Life Sciences™ and Contagion Live. All rights reserved.
Top Medical News
Invasive Nontyphoidal Salmonellosis: An Antimicrobial-Resistant Foe
September 24th 2022
Salmonella becomes more dangerous as antimicrobial resistance grows. Read about its most common manifestations.
Antibiotic Stewardship in Outpatient Care
September 23rd 2022
Although there are challenges for clinical and infectious disease pharmacists when trying to apply this concept, here are some considerations and strategies to employ stewardship in this setting.
Rapid, Reliable Diagnostic and PoC Tests Are Requisite for “Test to Treat"
September 23rd 2022
Progress in rapid diagnostic and point-of-care testing propelled by the pandemic can improve timeliness and precision of anti-infective treatment.
HCV Not Associated With Myocarditis Risks for Young HIV Patients
September 23rd 2022
However, according to one study the risk of heart inflammation increases with age and amplifies in patients with hepatitis C (HCV) compared to patients without HCV.
FDA Committee Recommends Approval for Rebyota (RBX2660) to Treat Recurrent C Difficile
September 22nd 2022
The Vaccines and Related Biological Products Advisory Committee's (VRBPAC) positive vote follows the committee’s review of the data from the biologics license application (BLA) for RBX2660.
10 Years After HIV PrEP Approval, Uptake Lowest Among Highest Risk Groups
August 9th 2022
Expanding Medicaid and reducing stigma can bolster equitable HIV PrEP access, Dr. Patrick Sullivan says.
Biktarvy Effective for HIV Patients Coinfected With Hepatitis B
August 1st 2022
At AIDS 2022, Gilead presented data suggesting Biktarvy was a safe and effective complete HIV treatment regimen, including for those coinfected with hepatitis B.
Fostemsavir Improves Outcomes for Treatment-Resistant HIV Patients
July 30th 2022
After 5 years of treatment, fostemsavir improved immunologic response and virologic outcome in patients with highly resistant HIV infection.
The Patient Impact of CDI, Preventing Reoccurrence
June 1st 2022
A clinician discusses the disease burden of reoccurring CDI, but sees a silver lining in the new investigational therapies potentially changing the treatment paradigm for the better.
September 22, 2022 6:00 PM
By John Parkinson
September 22, 2022 3:00 PM
By J. Drew Zimmer, PharmD, BCPS *
September 22, 2022 2:05 PM
By Rachel Lutz
September 21, 2022 4:00 PM
By Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS*
September 21, 2022 2:30 PM
By Laurie Saloman, MS
September 21, 2022 2:15 PM
By Paul Feuerstadt, MD
September 21, 2022 2:06 PM
By Paul Feuerstadt, MD
September 20, 2022 5:00 PM
By Nina Cosdon
September 20, 2022 1:09 PM
By Kyle Crooker, MD
September 20, 2022 12:15 PM
By Jonna Lorenz
